Navigation Links
Pharmasset to Present at the Natixis Bleichroeder Hidden Gems Conference on Monday, October 13th
Date:10/8/2008

PRINCETON, N.J., Oct. 8 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS) management will present at the Natixis Bleichroeder Hidden Gems Conference being held from October 13-14, 2008 at the Waldorf Astoria in New York City. Michelle Berrey, Pharmasset's Chief Medical Officer, will provide an overview of the company on Monday, October 13, 2008, at 11:30 AM (ET).

About Pharmasset

Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).

Pharmasset is currently developing three product candidates. Clevudine, for the treatment of chronic HBV infection, is enrolling Phase 3 clinical trials for registration in North, Central and South America and Europe. Clevudine is already approved for HBV in South Korea and marketed by Bukwang Pharmaceuticals in South Korea under the brand name Levovir. R7128, an oral treatment for chronic HCV infection, is in a 4-week Phase 1 clinical trial in combination with Pegasys(R) plus Copegus(R) through a strategic collaboration with Roche. Racivir, which is being developed for the treatment of HIV in combination with other approved HIV drugs, has completed a Phase 2 clinical trial.

Pegasys(R) and Copegus(R) are registered trademarks of Roche.

Contact

Richard E.T. Smith

Vice President of Investor Relations

richard.smith@pharmasset.com

Office: +1 (609) 613-4181


'/>"/>
SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related biology technology :

1. Pharmasset to Present at the JMP Securities Healthcare Focus Conference on Monday, October 6th
2. Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders
3. Pharmasset to Present at the Upcoming Citibank and Morgan Stanley Investor Conferences
4. Pharmasset to Present at the Canaccord Adams Global Growth Conference on Tuesday, August 12th
5. Pharmasset Announces $25.9 Million Registered Direct Offering of Common Stock
6. Pharmasset Joins Russell 3000 Index
7. Pharmasset to Present at the Needham & Co. Biotechnology and Medical Technology Conference on Wednesday, June 11th
8. Pharmasset Selected to Join the NASDAQ Biotechnology Index
9. Pharmasset to Present at the Morgan Stanley Global Healthcare Conference on Wednesday, April 30th
10. Pharmasset Adds Two Cohorts to R7128 Hepatitis C Study
11. Pharmasset to Present at the Canaccord Adams Hepatitis C Conference on Wednesday, April 9th
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... , May 24, 2013 InspireMD, ... in embolic protection stents, announced that Alan Milinazzo ... Craig Shore , the Company,s Chief Financial ... Conference on Thursday May 30, 2013 at The Pfister Hotel, ... The format of the conference includes a number ...
(Date:5/24/2013)... 24, 2013 This market report ... kinase profiling carried out in May 2013. The ... breakdown of the responses for each question, its ... It also highlights some interesting differences, particularly between ... bottom-up models were developed to estimate the in ...
(Date:5/24/2013)... OK (PRWEB) May 24, 2013 The ... casualties. And following its ravage, the mayor of Moore, one ... for new houses, said a report from cnn.com. Reaching out ... tornado victims complimentary Molderizer and Safe Shield to counter the ... the report published on May 22, 2013, caused 24 deaths, ...
(Date:5/24/2013)... Quincy Bioscience, a leading research company ... proteins to support healthy living, is pleased to ... apoaequorin in Food and Chemical Toxicology ... Industrial Biological Research Association. , The objective ... effects, if any, of apoaequorin, in rats following ...
Breaking Biology Technology:InspireMD To Participate In Benchmark Investor Conference On May 30th 2InspireMD To Participate In Benchmark Investor Conference On May 30th 3InspireMD To Participate In Benchmark Investor Conference On May 30th 4Kinase Market Profiling - In House & Outsourced Trends 2015 Forecast in New Research Report at ReportsnReports.com 2Kinase Market Profiling - In House & Outsourced Trends 2015 Forecast in New Research Report at ReportsnReports.com 3Kinase Market Profiling - In House & Outsourced Trends 2015 Forecast in New Research Report at ReportsnReports.com 4Mayor of Oklahoma-Tornado-Impaired Town Proposes Storm Shelter Bill, My Cleaning Products Offers Complimentary Molderizer and Safe Shield to Help Victim with Looming Mold 2Safety Assessment Study of Apoaequorin Published in Food and Chemical Toxicology 2
... JERUSALEM and NEEDHAM, Massachusetts, October 15 /PRNewswire-FirstCall/,-- ... launching at this week,s American,Society of Anesthesiologists ... total,solution Microstream(R) Monitoring System (MSM(TM)), powered by ... wireless technology for,continuous central station monitoring, is ...
... PALO ALTO, Calif., Oct. 15 Telik, Inc.,(Nasdaq: ... and Drug Administration (FDA),has removed the partial hold ... follows a complete review of TELCYTA data by,the ... development. Telik, Inc. of Palo Alto, CA ...
... Lower Dose Associated with Fewer Adverse Events in Healthy ... ... (NYSE: GSK ) HIV protease inhibitor LEXIVA(R),(fosamprenavir calcium) may now be ... of protease inhibitors in the,bloodstream. The U.S. Food and Drug Administration ...
Cached Biology Technology:Oridion Launches its Fully Integrated Remote Monitoring System and SARA Software for Improved Patient Safety 2Oridion Launches its Fully Integrated Remote Monitoring System and SARA Software for Improved Patient Safety 3Oridion Launches its Fully Integrated Remote Monitoring System and SARA Software for Improved Patient Safety 4FDA Removes Partial Hold on TELCYTA Clinical Development 2FDA Approves Administration of LEXIVA(R) with Lower Dose of 'Boosting' Medication Ritonavir 2FDA Approves Administration of LEXIVA(R) with Lower Dose of 'Boosting' Medication Ritonavir 3FDA Approves Administration of LEXIVA(R) with Lower Dose of 'Boosting' Medication Ritonavir 4
(Date:5/23/2013)... are billions of animal and plant specimens from birds, ... stacked, stored and preserved in jars and collection drawers. ... to understanding how the Earth,s biodiversity is changing in ... only the information were easily accessible. , A new ... a team from the University of Colorado Boulder, is ...
(Date:5/22/2013)... Forest Service scientists are part of "Landscapes of Resilience", ... Foundation, will examine how collaborative planning and stewardship of ... , The TKF Foundation announced today that Landscapes of ... funding. In addition to research on the role of ... the 3-year, $585,000 grant will contribute to the creation ...
(Date:5/22/2013)... and engineers must join together in a major new ... a crisis in providing Earth,s people with clean water ... focus of a comment article in the current edition ... newsmagazine of the American Chemical Society (ACS), the world,s ... L. Sedlak, Ph.D., and Jerald L. Schnoor, Ph.D., explain ...
Breaking Biology News(10 mins):CU-Boulder helps tap crowds to digitize museum records of bugs and plants 2CU-Boulder helps tap crowds to digitize museum records of bugs and plants 3CU-Boulder helps tap crowds to digitize museum records of bugs and plants 4'Landscapes of Resilience' to study how people use nature as a source of recovery 2
... lean on their national oil companies in ways that ... prices for the rest of the world, according to ... companies, like Saudi Aramco, Petrleos de Venezuela and China ... oil reserves, dwarfing the ExxonMobils of the world. ...
... DENVER - As oncologists already know and newly diagnosed ... to patients is increasingly becoming dependent on the specific ... cancer moves from being one common disease to multiple ... getting access to the right treatment within clinical trials ...
... medical community a new way of figuring out exactly how ... functions. University of Central Florida Engineering Assistant Professor Shaojie ... the subunits that make up RNA (ribonucleic acid). ... along with DNA and proteins. Knowing how all three ...
Cached Biology News:Book examines state-owned oil firms, prices and pollution 2Book examines state-owned oil firms, prices and pollution 3Using online patient communities and new trial approaches to optimize clinical research 2Using online patient communities and new trial approaches to optimize clinical research 3